Strategies and challenges for the next generation of antibody-drug conjugates

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) are a rapidly expanding class of cancer therapeutics.
• The success of early ADCs has spurred extensive research and clinical trials for new candidates.
• Lessons from first-generation ADCs have informed the development of improved second- and third-generation therapies.

Purpose of the Study:

• To review strategies for developing advanced antibody-drug conjugates.
• To discuss key considerations in ADC design, including target selection, drug choice, linker technology, and conjugation chemistry.
• To highlight current priorities in ADC research, focusing on antibody engineering and novel mechanisms of action.

Main Methods:

• Literature review of antibody-drug conjugate research and development.
• Analysis of strategies for ADC component selection (antigens, drugs, linkers).
• Discussion of conjugation chemistries, including bioorthogonal approaches.

Main Results:

• First-generation ADCs provided critical insights for developing more effective second-generation therapies with enhanced drug conjugation and stability.
• Ongoing research focuses on third-generation ADCs, emphasizing site-specific conjugation for homogeneity and stability.
• Key areas of investigation include optimizing target antigen and cytotoxic drug selection, linker design, and exploring new conjugation chemistries and mechanisms of action.

Conclusions:

• The evolution of ADCs from first to third generation demonstrates significant progress in oncology therapeutics.
• Site-specific conjugation and novel chemistries are crucial for enhancing ADC homogeneity, stability, and efficacy.
• Continued research into target selection, drug payloads, and conjugation strategies is essential for advancing ADC development and addressing toxicity concerns.